THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO D

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR

THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,

IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH

Tiziana Announces Publication of Registration

Statement on Form F-1 and

Proposed U.S. Public Offering of ADSs

New York and London, August 6, 2019 -

Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a U.S. and

U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology

and immunology, today announces the commencement of an underwritten public offering in the United States of American Depositary

Shares ("ADSs"), representing ordinary shares of nominal value 0.03 each in the capital of the Company

("Ordinary Shares") on the NASDAQ Global Market (the "Offering"). There can be no assurance

as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The price for the Offering

has not yet been determined.

All ADSs to be sold in the Offering will

be offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering will be within existing

shareholder authorities.

ThinkEquity, a division of Fordham Financial

Management, Inc., is acting as the representative of the underwriters in the Offering.

The Offering is being made only by means

of a prospectus, which, for the avoidance of doubt, will not constitute a "prospectus" for the purposes of the Prospectus

Regulation (as defined below) and has not been reviewed by any competent authority in any Member State (as defined below).

When available, copies of the preliminary

prospectus relating to and describing the terms of the Offering may be obtained from ThinkEquity, a division of Fordham Financial

Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email

at prospectus@think-equity.com. Electronic copies of the preliminary prospectus will also be available on the website of the SEC

A registration statement relating to these

securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy

these securities be accepted, prior to the time the registration statement becomes effective. This announcement shall not constitute

an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any

state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under

the securities laws of any such state or jurisdiction.

The person who arranged for the release

of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

Tiziana Life Sciences is a UK biotechnology

company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. We

believe Foralumab is the only fully human anti-CD3 mAb in clinical development in the world. This compound has potential application

in a wide range of autoimmune and inflammatory diseases, such as NASH, primary biliary cholangitis (PBS), ulcerative colitis, MS,

type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response

For readers in the European Economic

In any member state in the European Economic

Area (each, a "Member State"), this announcement is only addressed to and directed at qualified investors in that

Member State within the meaning of the Prospectus Regulation. The term "Prospectus Regulation" means Regulation

For readers in the United Kingdom

This announcement, in so far as it constitutes

an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets

Act 2000, as amended) in connection with the securities which are the subject of the Offering described in this announcement or

otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience

in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial

Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (iii) certain high

value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations

etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together

being referred to as "relevant persons"). The ADSs offered in the Offering are only available to, and any invitation,

offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person

who is not a relevant person should not act or rely on this announcement or any of its contents.

Forward-Looking Statements

Certain statements made in this announcement

are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Ordinary Shares

in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations,

estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,' intends,'

plans,' believes,' seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These statements

are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of

which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those

expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders

not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this

announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements

are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements

to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law

or by any appropriate regulatory authority.

For further enquiries: